Parallel Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History
Parallel Advisors, LLC
- $4.18 Billion
- Q3 2024
A detailed history of Parallel Advisors, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,879 shares of APLS stock, worth $51,559. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,879
Previous 1,629
15.35%
Holding current value
$51,559
Previous $62,000
12.9%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding APLS
# of Institutions
309Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$427 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$326 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$305 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$269 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$159 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.01B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...